Polyrizon (NASDAQ:PLRZ) Downgraded by Wall Street Zen to Sell

Polyrizon (NASDAQ:PLRZ) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Polyrizon in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Polyrizon currently has a consensus rating of “Sell”.

Polyrizon Stock Performance

Shares of NASDAQ PLRZ opened at $12.00 on Friday. Polyrizon has a one year low of $2.88 and a one year high of $2,235.00. The business has a 50-day moving average price of $13.83 and a two-hundred day moving average price of $9.83.

Polyrizon (NASDAQ:PLRZ) last posted its quarterly earnings results on Wednesday, March 25th. The company reported $2.81 earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Polyrizon

An institutional investor recently bought a new position in Polyrizon stock. Jane Street Group LLC bought a new position in shares of Polyrizon Ltd. (NASDAQ:PLRZ) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 14,032 shares of the company’s stock, valued at approximately $119,000. Jane Street Group LLC owned about 1.35% of Polyrizon at the end of the most recent reporting period.

Polyrizon Company Profile

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.